News and Events => Science & Medical News => Topic started by: Stochastic on February 22, 2015, 07:43:35 AM Return to Full Version
Title: Review - Hormone therapy in transgender adults is safe with provider supervision
Post by: Stochastic on February 22, 2015, 07:43:35 AM
Post by: Stochastic on February 22, 2015, 07:43:35 AM
Another good synthesis paper. The full article is available for reading at the below link. Good information for both FTM and MTF. I am not in the health field, so I would welcome any thoughts after reading the paper.
Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals
http://www.jctejournal.com/article/S2214-6237(15)00049-6/abstract?cc=y
J.D. Weinand and J.D. Safer
Journal of Clinical & Translational Endocrinology, 2014
Abstract
Introduction
Some providers report concern for the safety of transgender hormone therapy (HT).
Methods
This is a systematic literature review of HT safety for transgender adults.
Results
Current literature suggests HT is safe when followed carefully for certain risks. The greatest health concern for HT in transgender women is venous thromboembolism. HT among transgender men appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in cancer prevalence or mortality due to transgender HT.
Conclusion
Although current data support the safety of transgender HT with physician supervision, larger, long-term studies are needed in transgender medicine.
Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals
http://www.jctejournal.com/article/S2214-6237(15)00049-6/abstract?cc=y
J.D. Weinand and J.D. Safer
Journal of Clinical & Translational Endocrinology, 2014
Abstract
Introduction
Some providers report concern for the safety of transgender hormone therapy (HT).
Methods
This is a systematic literature review of HT safety for transgender adults.
Results
Current literature suggests HT is safe when followed carefully for certain risks. The greatest health concern for HT in transgender women is venous thromboembolism. HT among transgender men appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in cancer prevalence or mortality due to transgender HT.
Conclusion
Although current data support the safety of transgender HT with physician supervision, larger, long-term studies are needed in transgender medicine.